Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Lawsuit - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm is pursuing a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 27, 2025 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia's stock may experience continued volatility due to the pending lawsuit and significant organizational changes, including research program halt and workforce reduction.
The lawsuit and company reorganization directly impact Intellia's stock, suggesting potential financial and reputational damage. The stock price already dropped following the announcement, and ongoing legal proceedings could further pressure the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100